Newborn Hearing Screening

Newborn Hearing Screening

No Results

No Results

processing….

Universal screening programs have been implemented across the United States. Hearing loss occurs often enough in the general population to justify the legislation for universal hearing screening programs across the United States.

Hearing loss is one of the most common congenital anomalies, occurring in approximately 2-4 infants per 1000. Prior to implementation of universal newborn screening, testing was conducted only on infants who met the criteria of the high-risk register (HRR). It was found that the HRR was not enough, given that as many as 50% of infants born with hearing loss have no known risk factors. Reliable screening tests that minimize referral rates and maximize sensitivity and specificity are now readily available.

Early identification and intervention can prevent severe psychosocial, educational, and linguistic repercussions. Infants who are not identified before 6 months of age have delays in speech and language development. Intervention at or before 6 months of age allows a child with impaired hearing to develop normal speech and language, alongside his or her hearing peers.

A study from the Centers for Disease Control and Prevention (CDC) found that in the United States between 2006 and 2012, in newborns screened for hearing loss, the rate of hearing impairment diagnoses for those who did not pass their final screening test rose from 4.8% to 10.3%, while the rate of enrollment in early intervention services among children diagnosed with hearing loss grew from 55.4% to 61.7%. According to the study, however, reporting is inconsistent with regard to diagnostic test results (as opposed to screening results) and enrollment in early intervention. [1]

See Table 1 below for common misconceptions held by the public about hearing loss and its identification in infants. Universal newborn hearing screening is essential to the normal speech and language development in the large number of infants born with hearing loss in the United States each year.

Table 1. Common Misconceptions Held by the Public and the Clinical Facts (Open Table in a new window)

Misconception

Clinical Fact

Parents will know if their child has a hearing loss by the time their child is 2-3 months of age.

Prior to the universal screening, the average age at which children were found to have a hearing loss is 2-3 years. Children with mild-to-moderate hearing loss were often not identified until 4 years of age.

Parents can identify a hearing loss by clapping their hands behind the child’s head.

Children can compensate for a hearing loss. They use visual cues, such as shadows or parental expressions and reactions, or they may feel the breeze caused by the motion of the hands.

The HRR is all that is needed to identify children with hearing loss.

The HRR misses approximately 50% of all children with hearing loss.

Hearing loss does not occur often enough to justify the use of universal screening programs.

Hearing loss affects approximately 2-4 per 1000 live births, and it has been estimated to be one of the most common congenital anomalies.

Tests are not reliable and cause too many infants to be referred to specialists.

Referral rates are as low as 5-7%.

There is no rush to identify a hearing loss. The loss does not need to be identified until a child is aged 2-3 years.

Children identified when they are older than 6 months can have speech and language delays. Children identified when they are younger than 6 months do not have these delays and are equal to their hearing peers in terms of speech and language.

Children younger than 12 months cannot be fitted with hearing aids.

Children as young as 1 month of age can be fit with and benefit from hearing aids.

 

An image depicting newborn hearing screening can be seen below.

The ability to hear during the early years of life is critical for the development of speech, language, and cognition.

Retrospective studies of large universal newborn hearing screening programs have shown that permanent hearing loss is one of the most common abnormalities present at birth. In 1999, the American Academy of Pediatrics Task Force on Newborn and Infant Hearing stated, “significant bilateral hearing loss has been shown to be present in approximately 1 to 3 per 1000 newborns in the well-baby nursery population, and in approximately 2 to 4 per 1000 infants in the intensive care unit population.” [2] Data from the newborn hearing-screening programs in Rhode Island, Colorado, and Texas show that 2-4 of every 1000 neonates have hearing loss (see Table 2 below). [3, 4, 5] A retrospective study conducted by Connolly et al in 2005 found that 1 of every 811 infants without risk factors and 1 of every 75 infants with risk factors have hearing loss. [6] The prevalence of hearing loss may continue to change as more data becomes available from universal newborn hearing screening programs.

Table 2. Studies Regarding the Prevalence of Hearing Loss in Newborns (Open Table in a new window)

Investigator, Year

State

Rate of Hearing Loss

Study Population

Connolly, 2005 [6]

Mississippi

1.00 / 811 (no risk)

1.00 / 75 (high risk)

17,602

Finitzo, 1998 [5]

Texas

3.14 / 1000

54,228

Vohr, 1998 [3]

Rhode Island

2.00 / 1000

53,121

Downs, 1995 [4]

Colorado

3.20 / 1000

14,404

The prevalence of hearing loss has been shown to be greater than that of most other diseases and syndromes (eg, phenylketonuria, sickle cell disease) screened at birth. The occurrence of hearing loss has been estimated to be more than twice that of other screenable newborn disorders combined (see Table 3 below).

Table 3. Prevalence of Metabolic Disorders Screened at Birth in Texas* (Open Table in a new window)

Disorder

Rate per 100,000

Adrenal hyperplasia

2

Galactosemia

2

Phenylketonuria

3

Hypothyroid disease

28

Sickle cell disease

47

*Finitzio, 1999

In the at-risk population, which includes neonates who spend time in the newborn intensive care unit (NICU), the occurrence of hearing loss is even higher. Risk factors for hearing loss specifically found in this population include, but are not limited to, use of high frequency ventilation, hyperbilirubinemia, low birth-weight, and exposure to ototoxic medications. [7] While these infants are at-risk for hearing loss at birth, studies have shown increased risk in this population for progressive and/or late-onset hearing loss. In a comprehensive study of extremely low birth-weight children, the incidence and severity of hearing impairment increased significantly from 5% to 13% (P=0.01) over a 24-year period. As these infants are identified as being at-risk for progressive or late-onset hearing loss, it is essential that they are not only screened at birth, but are followed regularly for audiological assessment and are not lost to follow-up. [8]

Prior to the implementation of universal newborn hearing screening, only infants identified as being at high risk for hearing loss on the basis of the high-risk register (HRR) were routinely screened. According to the Joint Committee on Infant Hearing (JCIH) 2000 Position Statement, the risk factors for newborns are as follows: [9]

Family history of permanent childhood sensorineural hearing loss

In utero infection such as cytomegalovirus, rubella toxoplasmosis, or herpes

Craniofacial anomalies, including those with morphological abnormalities of the pinna and ear canal

Neonatal indicators, specifically hyperbilirubinemia at a serum level requiring exchange transfusion, persistent pulmonary hypertension of the newborn (PPHN) associated with mechanical ventilation, and conditions requiring the use of extracorporeal membrane oxygenation (ECMO)

Postnatal infections associated with sensorineural hearing loss, including bacterial meningitis

Stigmata or other findings associated with a syndrome known to include a sensorineural or conductive hearing loss or eustachian tube dysfunction

Syndromes associated with progressive hearing loss such as neurofibromatosis, osteopetrosis, and Usher syndrome

Neurodegenerative disorders, such as Hunter syndrome, or sensory motor neuropathies, such as Charcot-Marie-Tooth syndrome

Parental or caregiver concern regarding hearing, speech, language, and/or developmental delay

Head trauma

Recurrent or persistent otitis media with effusion lasting for at least 3 months

Use of the HRR as the primary indicator for screening of newborns for hearing loss was inadequate. In 1999, Finitzio and Crumley reported that, according to the identification rates currently reported from widespread screening programs, approximately 8,000-16,000 newborns are born with hearing loss each year. [10] Of these, 50% are discharged home from the well-baby nursery with no known risk factors for hearing loss, according to the National Institutes of Health (NIH). [11] Although these risk factors should not be ignored, a program in which only neonates meeting the HRR criteria are screened was found to exclude as many as 50% of newborns with significant congenital hearing loss.

In addition, an Australian study found that the ages of diagnosis of congenital hearing loss following universal newborn screening, risk factor screening, and opportunistic screening were 8.1, 16.2, and 22.5 months, respectively. [12]

An updated HRR is still used to identify children who are at risk for hearing loss. All newborns should be screened, regardless of risk. If a newborn passes the newborn hearing screening but has an identified risk for sensorineural and/or conductive hearing loss, these infants should be closely monitored for any changes in hearing status. Many states recommend that at-risk children should be evaluated by an audiologist every 6 months for the first 3 years of life. This helps to quickly identify hearing status changes so that intervention can occur, limiting any impact the hearing loss has on speech and language development.

As recently as 1988, the age at which hearing loss was identified in children in the United States was estimated to be 2.5 years. Although children who had severe-to-profound hearing loss or multiple disabilities were identified at or before age 2.5 years, children with mild-to-moderate hearing loss were often not identified until school age. [9] The implementation of universal hearing screening programs is beginning to lower this age. A study conducted by Connolly et al in 2005 indicated that, as a result of the universal newborn hearing screening program in place from 1997-2001, the mean age of diagnosis was 3.9 months, with a mean age of intervention of 6.1 months. [6]

Children with hearing loss typically experience significant delays in language development and academic achievement. Although the impact of a severe or profound hearing loss is well recognized, children with mild or moderate hearing loss also experience deficits in speech and language development. Studies have shown that hearing-impaired high school graduates have significantly lower average reading scores than those of their hearing peers, with deaf and hard-of-hearing students scoring at the fourth or fifth grade level.

The definition of early identification and intervention has evolved over the years. In the recent past, early identification was defined as intervention before the age of 18 months. The implementation of universal screening programs throughout the United States has caused the definition of early identification and intervention to be re-examined. Early identification can now be defined as diagnosis as early as age 3 months, with intervention by age 6 months. In 1994, Bess and Paradise challenged the need for earlier identification and intervention, stating that no evidence support the notion “that outcomes in children with congenital hearing loss are more favorable if treatment is begun early in infancy rather than later in childhood.” [13] Since then, many groups have refuted this statement.

In 1987, White and White reported that, in severely and profoundly deaf children, language scores were significantly better in those whose hearing loss was identified at an average age of 11.9 months, compared with scores in those whose loss was identified at an average age of 19.5 months. [14]

In 1995, Apuzzo and Yoshinaga-Itano found that infants identified when they were younger than 2 months had significantly higher language scores than those identified when they were older than 2 months, despite similar interventions in both groups. [15] In 1995, Robinshaw reported that children who were identified and who wore hearing aids by the age of 6 months acquired age-appropriate vocal communicative and linguistic skills well before children who were identified at a later age. [16]

Although all of the above studies demonstrate the importance of early identification and intervention, a study conducted in 1998 at the University of Colorado truly established the critical period of early identification and intervention, namely, younger than 6 months. [17, 18] In 1998, Yoshinaga-Itano and Sedey et al compared receptive and expressive language abilities in children with various degrees of hearing impairment with those of children with no hearing loss. Significant findings were as follows:

Children with hearing loss that is identified by age 6 months had significantly higher receptive, expressive, and total language quotients than those of children identified at 7-12, 13-18, 19-24, and 25-34 months.

This statistical difference was independent of the following demographic variables: age, sex, ethnicity, communication mode, degree of hearing loss, socioeconomic status, and presence or absence of other disabilities.

No significant differences in language ability were found among groups of children who were identified when they were older than 6 months.

In other words, even children identified as early as age 7-12 months had lower receptive and expressive language quotients than those of children identified by age 6 months. No significant difference was found between children identified at age 7-12 months and those identified at age 25-30 months.

The importance of early identification and intervention has been clearly demonstrated. Identification and intervention before age 6 months can have a significant impact on the development of expressive and receptive language. The finding that language scores were not significantly different between the children identified later truly establishes the critical period of early identification and intervention to be within the first 6 months of life.

Healthcare professionals have long supported the need for early identification and intervention in infants and children with hearing loss. The main goal of early identification and intervention programs is to improve the speech and language development of infants and children who are deaf or hard of hearing, thereby improving their academic and vocational achievements. Although the need for successful universal newborn hearing screening programs cannot be denied, the legislative support, technology, and expertise needed to implement such programs on a national level has only recently been realized.

Following the Individuals with Disabilities Education Act of 1989, the Rhode Island Hearing Assessment Project (RIHAP) was developed in 1990 through funding from the US Department of Education and the US Public Health Service. This project was designed to systematically evaluate the effectiveness of transient evoked otoacoustic emissions (TEOAEs) in screening newborns for hearing loss.

In 1994, the Joint Committee on Infant Hearing (JCIH) released a position statement endorsing the goal of universal identification of infants with hearing loss as early as possible, with early identification by age 3 months and intervention by age 6 months. [19] In 2000, the JCIH modified the high-risk register (HRR) to aid in the identification of newborns at high risk for permanent hearing loss, particularly those at risk for progressive hearing loss, through age 2 years. [20] The JCIH 2000 Position Statement was designed to meet the goals of Healthy People 2000 (US Department of Health and Human Services Public Health Service, 1990) and 2010 (US Department of Health and Human Services, 2000), the 1993 NIH Consensus Statement, and the American Academy of Audiology position statement. [21, 11] The American Academy of Pediatrics endorsed this position statement.

Although all of these position statements support the need for early identification and intervention in infants with hearing loss, recommendations from both the JCIH and the American Academy of Audiology include the screening of all newborns for hearing loss prior to their discharge home from birthing hospitals.

The implementation of statewide systems for the universal hearing screening of newborns is gaining momentum. Currently, legislation for newborn hearing screening has been passed in many states. In some states, legislation has not passed but voluntary newborn hearing screenings are performed at most birthing hospitals.

The following states passed legislation for universal screening of hearing in newborns in the years indicated:

Alabama – 2008

Alaska – 2006

Arizona – 2005

Arkansas – 1999

California – 1998

Colorado – 1997

Connecticut – 1997

District of Columbia – 2001

Florida – 2000

Georgia – 1999

Hawaii – 1990

Illinois – 1999

Indiana – 1999

Iowa – 2003

Kansas – 1999

Kentucky – 2000

Louisiana – 1999

Maine – 1999

Maryland – 1999

Massachusetts – 1997

Michigan – 2002

Mississippi – 1997

Missouri – 1999

Montana – 2001

Nebraska – 2000

Nevada – 2000

New Hampshire – 2000

New Jersey – 2000

New Mexico – 2001

New York – 1999

North Carolina – 1999

Ohio – 2002

Oklahoma – 2000

Oregon – 1999

Pennsylvania – 2001

Rhode Island – 1992

South Carolina – 2000

Tennessee – 2008

Texas – 1999

Utah – 1998

Virginia – 1998

West Virginia – 1998

Wisconsin – 1999

Wyoming – 1999

The new JCIH 2007 Position Statement was released in early October 2007. [22] The following is a list of some of the significant changes from the previous statement:

The definition of targeted hearing loss was expanded to include neural hearing loss (eg. auditory neuropathy/dyssynchrony).

Separate protocols are recommended for neonatal intensive care units (NICUs) and well-baby nurseries. Auditory brainstem response screenings are recommended for all NICU babies, as well as babies admitted for greater than 5 days, so that neural hearing loss will not be missed.

Referrals should be made directly to an audiologist for comprehensive testing to include diagnostic auditory brainstem response (ABR) for all infants who do not pass ABR screening in the NICU.

Rescreening of all infants should include re-evaluation of both ears, even if the infant only failed one ear in the initial screening.

Audiologists with expertise in evaluating newborns should conduct diagnostic evaluations.

Children identified with hearing loss should be fit with amplification within 1 month of diagnosis.

A genetics consultation should be offered to families of infants diagnosed with hearing loss.

All children identified with hearing loss should undergo an evaluation by an otolaryngologist and have at least one examination to assess visual acuity with a pediatric ophthalmologist.

All children with any degree of bilateral or unilateral hearing loss should be considered eligible for early intervention services.

Families should be made aware of all communication options and available hearing technologies (presented in an unbiased manner).

Early intervention services should be provided by professionals with expertise in hearing loss.

Based on data from 134 children, a study by Ghogomu et al indicated that institution of a universal newborn hearing screening program in Missouri reduced the mean age of detection of pediatric unilateral sensorineural hearing loss from 4.4 years to 2.6 years and increased the rate at which such hearing loss is detected by age 6 months from 3% to 42%. [23] According to a study involving patients at a pediatric teaching hospital in Canada, universal newborn hearing screening lowered the median age at which mild bilateral or unilateral hearing loss was detected from 5 years to 0.8 years. [24]

Auditory brainstem response (ABR), otoacoustic emissions (OAEs), and automated ABR (AABR) testing have all been used in newborn hearing-screening programs. For 20 years, manual or diagnostic ABR testing has been a reliable means of assessing auditory function from the eighth nerve through the auditory brainstem. A modified screening version of the ABR test, called the AABR test, has been available for screening since approximately 1987. The discovery of OAEs by David Kemp in 1978 allowed the development of an alternative screening technology that has become commonplace in hospitals across the nation. [25] The 2 methods used in most universal hearing-screening programs are automated OAEs and AABR. Behavioral audiometry is not sufficiently sensitive or specific for use in a screening program.

OAEs are used to assess cochlear integrity and are physiologic measurements of the response of the outer hair cells to acoustic stimuli. They serve as a fast objective screening test for normal preneural cochlear function. To measure OAEs, a probe assembly is placed in the ear canal, tonal or click stimuli are delivered, and the OAE generated by the cochlea is measured with a microphone.

Currently, 2 types of evoked OAE measurements are used for newborn hearing screening: transient evoked otoacoustic emissions (TEOAEs) and distortion product otoacoustic emissions (DPOAEs). Provided that the patient’s middle ear function is normal, these measurements can be used to assess cochlear function for the 500-6000 Hz frequency range. The presence of evoked OAE responses indicates hearing sensitivity in the normal to near-normal range. [26]

OAEs are fast, efficient, and frequency-specific measurements of peripheral auditory sensitivity. However, the effectiveness of the test is reduced by contamination with low-frequency ambient noise in a busy nursery, vernix in the ear canal, or any middle ear pathology.

OAEs are not a sufficient screening tool in infants who are at risk for neural hearing loss (eg, auditory neuropathy/dyssynchrony). Any infant in the NICU or in the hospital for more than 5 days should undergo an ABR screening so that the presence of auditory neuropathy is not missed. Cochlear function, and therefore OAE measurements, are usually normal in infants and children with this type of hearing loss.

AABR is an electrophysiologic measurement that is used to assess auditory function from the eighth nerve through the auditory brainstem. AABR measurements are generally obtained by placing disposable surface electrodes high on the forehead, on the mastoid, and on the nape of the neck (see the image below). The click stimulus (usually set at 35 dB hearing level [HL]) is delivered to the infant’s ear via small disposable earphones designed to attenuate background noise. Most AABR systems compare an infant’s waveform with that of a template developed from normative ABR infant data. A pass or fail response is determined from this comparison. Most commercially available systems can be used as an effective screening tool in infants younger than 6 months.

The AABR method produces a simple pass or fail result without requiring interpretation, and the test can be conducted in the presence of background noise. However, it lacks frequency-specific information and requires increased preparation time prior to testing.

The AABR test is solely a screening technique designed to identify infants who require follow-up testing. It cannot be used to determine the degree or nature of the hearing loss.

A study by Johnson et al reported that in healthy newborns, failure rates for AABR evaluation were lower when testing was delayed. The AABR failure rate in newborns tested less than 24 hours postnatally was 13.3%, compared with 3.8% in those tested at or after 48 hours. The investigators also found a greater repeat testing failure rate among infants who underwent initial AABR testing at age 36 hours or above than among those who were initially tested earlier. Moreover, 18.6% of neonates who failed a final AABR screening test at age 48 hours or older were diagnosed with sensorineural hearing loss, while this diagnosis was made in just 2.8% of those whose final screening took place prior to 48 hours. [27]

Diagnostic ABR testing is generally not used in universal newborn hearing screening programs because of the length of the procedure, the cost, and the need for an audiologist to perform the test and interpret the results. Like AABRs, diagnostic ABRs are electrophysiologic measurements that reflect auditory function from the eighth nerve through the auditory brainstem.

ABR recordings are generally obtained by placing disposable surface electrodes on the forehead and on both mastoids. Responses are typically measured from the forehead to the ipsilateral mastoid. ABR waveforms are obtained in response to abrupt click stimuli delivered in rapid pulse trains through insert earphones.

Unlike the AABR test, which elicits a response to a fixed 35-dB HL click, the intensity of the stimulus is varied in the manual ABR test to determine the lowest level required to evoke a clear and repeatable response. This form of ABR testing allows the audiologist to determine not only the severity of the hearing loss but also the nature of the hearing loss (ie, sensorineural, conductive, or neural) by using both air and bone conduction stimulation. When a click is used to evoke the ABR, information regarding hearing sensitivity is restricted to approximately 1000-4000 Hz. If necessary, an ABR can be elicited by tone burst stimulation to determine the configuration of a hearing loss.

The ABR is not used to assess hearing in a perceptual sense; rather, it helps in evaluating the integrity of the peripheral auditory system from which estimates of hearing can be derived.

Diagnostic ABR tests can be used to determine the degree of hearing loss and also the nature of the loss. However, they are not efficient for a screening program. ABR techniques should be used for follow-up diagnostic procedures.

Infants who do not pass an initial hearing screening at birth should return for follow-up testing within 1 month. This follow-up allows for multiple testing sessions, medical intervention, parent counseling, and appropriate amplification measures to be initiated before the age of 6 months. The goal for identification and intervention by 6 months is important for language development, and diagnosis before this critical age can prevent the need for sedation. As the age of an infant increases, the ability to obtain a full diagnostic test battery decreases. If follow-up is delayed, sedation may be required in order to obtain electrophysiological measures.

Diagnostic OAE and ABR testing is recommended for any infant who does not pass the second screening session. Both tests are necessary to differentially diagnose an infant’s hearing impairment. OAE tests are used to assess the outer, middle, and inner ear portions of the auditory system. ABR testing helps in assessing the whole system, from the periphery to the auditory nerve and brainstem (see Table 4). Traditionally, diagnostic ABR results differentiate between conductive loss and sensorineural loss.

However, with the addition of OAEs, separating a purely sensory loss, which occurs in the cochlea, from a purely neural loss is now possible. For example, an infant may have an abnormal ABR with normal OAEs. This type of neural hearing loss is known as auditory neuropathy, or auditory dyssynchrony, and has been described by Sininger and Starr in 2001. [28]

If a child is identified with a hearing loss, another specialized test may be necessary to obtain frequency-specific information in order to amplify appropriately. This frequency-specific information can be obtained by conducting either tone burst–evoked ABR or by auditory steady-state response testing (ASSR). ASSR has been found to be a very useful tool for providing discrete, frequency-specific information, especially in the presence of moderate-to-profound hearing loss. [20]

The following audiologic test battery should be conducted on any infant identified with hearing loss: air conduction ABR, bone conduction ABR, high-frequency tympanometry, otoacoustic emissions, acoustic stapedial reflexes, tone burst ABR and/or ASSR, and behavioral audiometry (when appropriate) to assess functional hearing. Reversing polarity during all diagnostic air conduction ABR testing should also be conducted to ensure that the response is truly neural and to rule out auditory neuropathy. The comprehensive diagnostic information obtained from the full test battery is beneficial when a plan for intervention and amplification is implemented. This information provides medical caregivers with a total picture of the patient’s auditory function, from the peripheral sensory structures through the brainstem.

Table 4. Assessment of the Auditory System by OAEs and ABRs/AABRs (Open Table in a new window)

Auditory Structure

OAEs

ABRs/AABRs

Outer ear

Yes

Yes

Middle ear

Yes

Yes

Inner ear

Yes

Yes

Auditory nerve

No

Yes

Auditory brainstem

No

Yes

The goal of any infant hearing screening program is to achieve a high level of both sensitivity and specificity. The ideal program should permit the identification of as many newborns as possible who do have a hearing loss (high sensitivity) and also to exclude as many newborns as possible who do not have a hearing loss (high specificity). With these goals in mind, the NIH Consensus Statement recommends that all screening programs should have a failure rate of no more than 5-7%, and the number of referrals be kept to a minimum. [11] In 2004, Hall, Smith, and Popelka reported an estimated sensitivity at 100%, specificity at 99.7%, overall referral rate of 2.0% and a positive predictive value of 83.3% in a study comprised of 300 infants. [29]

While AABR has been used for years on infants falling under the high-risk register (HRR), OAE screening has been shown to be a highly cost-effective tool. Several papers have described a combined AABR and OAE screening technique as an effective tool for maintaining low referral rates. [30, 31, 32, 33]

Programs in Rhode Island, Texas, and Colorado have demonstrated that a referral rate of 5-7% is obtainable. The TEOAE-based program in Rhode Island reported a higher average referral rate of 10% over a 4-year period. [3] Using AABR testing, the Colorado program reported a referral rate of 5%, whereas Texas hospitals achieved a 3.4% referral rate. [4, 5] Hospitals in Texas that used a 2-technology procedure of OAE testing followed by AABR testing had an average failure rate of 3% (see the image below). In a 2004 report, Hall, Smith, and Popelka suggest that a 2-stage approach can serve as a crosscheck to evaluate each type of testing. [29] A 2-stage AABR protocol used in Mississippi from 1997-2001 yielded a referral rate of 4.1% and a false-positive rate of 3.6%. [6] Some studies indicate that a 2-stage protocol may have a slightly higher referral rate than AABR alone, but a significant increase in referrals with TEOAEs and/or DPOAEs alone continued. [34]

Referral rates will always vary depending on the method of screening used in the program. This variation must be kept in mind when a protocol for screening is established. Referral rates are often higher initially, at the onset of a screening program, but they tend to decrease with experience. Given the increased understanding and identification of auditory neuropathy, an AABR screening protocol is recommended in the NICU setting and with any other at-risk infants. Although OAE screening continues to be cost effective in the well-baby nursery, OAE screening followed by AABR is a reliable protocol that results in low referral rates.

The identification of all newborns with hearing loss before age 6 months has now become an attainable realistic goal. In the past, parents and pediatricians often did not suspect a hearing loss until the age of 2-3 years, after important speech and language milestones have not been met. By the time these milestones are missed, the hearing-impaired child has already experienced irreversible delays in speech and language development.

Technology allows for the development of screening tools that are reliable and th

Williams TR, Alam S, Gaffney M, Centers for Disease Control and Prevention (CDC). Progress in identifying infants with hearing loss—United States, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015 Apr 10. 64 (13):351-6. [Medline]. [Full Text].

Erenberg A, Lemons J, Sia C, Trunkel D, Ziring P. Newborn and infant hearing loss: detection and intervention.American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998- 1999. Pediatrics. 1999 Feb. 103(2):527-30. [Medline].

Vohr BR, Carty LM, Moore PE, Letourneau K. The Rhode Island Hearing Assessment Program: experience with statewide hearing screening (1993-1996). J Pediatr. 1998 Sep. 133(3):353-7. [Medline].

Downs MP. Universal newborn hearing screening–the Colorado story. Int J Pediatr Otorhinolaryngol. 1995 Jul. 32(3):257-9. [Medline].

Finitzo T, Albright K, O’Neal J. The newborn with hearing loss: detection in the nursery. Pediatrics. 1998 Dec. 102(6):1452-60. [Medline].

Connolly JL, Carron JD, Roark SD. Universal newborn hearing screening: are we achieving the Joint Committee on Infant Hearing (JCIH) objectives?. Laryngoscope. 2005 Feb. 115(2):232-6. [Medline].

Kuzniewicz MW, Wickremasinghe AC, Wu YW, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics. 2014 Sep. 134 (3):504-9. [Medline]. [Full Text].

Synnes AR, Anson S, Baum J, Usher L. Incidence and pattern of hearing impairment in children with = 800 g birthweight in British Columbia, Canada. Acta Paediatr. 2012 Feb. 101(2):e48-54. [Medline].

JCIH. Year 2000 position statement: principles and guidelines for early hearing detection and intervention programs. Joint Committee on Infant Hearing, American Academy of Audiology, American Academy of Pediatrics, American Speech-Language-Hearing Association, and Directors of Speech and Hearing Programs in State Health and Welfare Agencies. Pediatrics. 2000 Oct. 106(4):798-817. [Medline].

Finitzo T, Crumley WG. The role of the pediatrician in hearing loss. From detection to connection. Pediatr Clin North Am. 1999 Feb. 46(1):15-34, ix-x. [Medline].

NIH. Early identification of hearing impairment in infants and young children. NIH Consens Statement. 1993 Mar 1-3. 11(1):1-24. [Medline].

Wake M, Ching TY, Wirth K, et al. Population Outcomes of Three Approaches to Detection of Congenital Hearing Loss. Pediatrics. 2016 Jan. 137 (1):1-10. [Medline].

Bess FH, Paradise JL. Universal screening for infant hearing impairment: not simple, not risk-free, not necessarily beneficial, and not presently justified. Pediatrics. 1994 Feb. 93(2):330-4. [Medline].

White SJ, White RE. The effects of hearing status of the family and age of intervention on receptive and expressive oral language skills in hearing-impaired infants. ASHA Monogr. 1987 Oct. (26):9-24. [Medline].

Apuzzo ML, Yoshinaga-Itano C. Early identification of infants with significant hearing loss and the Minnesota Child Development Inventory. Semin Hearing. 1995. 16:124-37.

Robinshaw HM. Early intervention for hearing impairment: differences in the timing of communicative and linguistic development. Br J Audiol. 1995 Dec. 29(6):315-34. [Medline].

Yoshinaga-Itano C, Apuzzo ML. Identification of hearing loss after age 18 months is not early enough. Am Ann Deaf. 1998 Dec. 143(5):380-7. [Medline].

Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics. 1998 Nov. 102(5):1161-71. [Medline].

AAP. American Academy of Pediatrics Joint Committee on Infant Hearing 1994 Position Statement. Pediatrics. 1995 Jan. 95(1):152-6. [Medline].

Luts H, Desloovere C, Kumar A, Vandermeersch E, Wouters J. Objective assessment of frequency-specific hearing thresholds in babies. Int J Pediatr Otorhinolaryngol. 2004 Jul. 68(7):915-26. [Medline].

HHS. Healthy People 2000: National Health Promotion and Disease Objectives. Washington, DC: US Department of Health and Human Services; 1990.

Executive Summary for JCIH Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. ASHA. 2007.

Ghogomu N, Umansky A, Lieu JE. Epidemiology of unilateral sensorineural hearing loss with universal newborn hearing screening. Laryngoscope. 2014 Jan. 124(1):295-300. [Medline]. [Full Text].

Fitzpatrick EM, Whittingham J, Durieux-Smith A. Mild bilateral and unilateral hearing loss in childhood: a 20-year view of hearing characteristics, and audiologic practices before and after newborn hearing screening. Ear Hear. 2014 Jan-Feb. 35(1):10-8. [Medline].

Kemp DT. Stimulated acoustic emissions from within the human auditory system. J Acoust Soc Am. 1978 Nov. 64(5):1386-91. [Medline].

Jedrzejczak WW, Konopka W, Kochanek K, Skarzynski H. Otoacoustic emissions in newborns evoked by 0.5kHz tone bursts. Int J Pediatr Otorhinolaryngol. 2015 Sep. 79 (9):1522-6. [Medline].

Johnson LC, Toro M, Vishnja E, et al. Age and Other Factors Affecting the Outcome of AABR Screening in Neonates. Hosp Pediatr. 2018 Mar. 8 (3):141-7. [Medline].

Sininger YS, Starr A. Auditory Neuropathy. A New Perspective on Hearing Disorders. Singular Thomson Learning: San Diego, Calif; 2001.

Hall JW 3rd, Smith SD, Popelka GR. Newborn hearing screening with combined otoacoustic emissions and auditory brainstem responses. J Am Acad Audiol. 2004 Jun. 15(6):414-25. [Medline].

Norton SJ, Gorga MP, Widen JE, Folsom RC, Sininger Y, Cone-Wesson B. Identification of neonatal hearing impairment: a multicenter investigation. Ear Hear. 2000 Oct. 21(5):348-56. [Medline].

Stewart DL, Mehl A, Hall JW 3rd, Thomson V, Carroll M, Hamlett J. Universal newborn hearing screening with automated auditory brainstem response: a multisite investigation. J Perinatol. 2000 Dec. 20(8 Pt 2):S128-31. [Medline].

Gorga MP, Preissler K, Simmons J, Walker L, Hoover B. Some issues relevant to establishing a universal newborn hearing screening program. J Am Acad Audiol. 2001 Feb. 12(2):101-12. [Medline].

Levit Y, Himmelfarb M, Dollberg S. Sensitivity of the Automated Auditory Brainstem Response in Neonatal Hearing Screening. Pediatrics. 2015 Sep. 136 (3):e641-7. [Medline]. [Full Text].

Lin HC, Shu MT, Lee KS, Lin HY, Lin G. Reducing False Positives in Newborn Hearing Screening Program: How and Why. Otol Neurotol. 2007 Sep. 28(6):788-792. [Medline].

Silva DP, Lopez PS, Ribeiro GE, Luna MO, Lyra JC, Montovani JC. The importance of retesting the hearing screening as an indicator of the real early hearing disorder. Braz J Otorhinolaryngol. 2015 Jul-Aug. 81 (4):363-7. [Medline].

Misconception

Clinical Fact

Parents will know if their child has a hearing loss by the time their child is 2-3 months of age.

Prior to the universal screening, the average age at which children were found to have a hearing loss is 2-3 years. Children with mild-to-moderate hearing loss were often not identified until 4 years of age.

Parents can identify a hearing loss by clapping their hands behind the child’s head.

Children can compensate for a hearing loss. They use visual cues, such as shadows or parental expressions and reactions, or they may feel the breeze caused by the motion of the hands.

The HRR is all that is needed to identify children with hearing loss.

The HRR misses approximately 50% of all children with hearing loss.

Hearing loss does not occur often enough to justify the use of universal screening programs.

Hearing loss affects approximately 2-4 per 1000 live births, and it has been estimated to be one of the most common congenital anomalies.

Tests are not reliable and cause too many infants to be referred to specialists.

Referral rates are as low as 5-7%.

There is no rush to identify a hearing loss. The loss does not need to be identified until a child is aged 2-3 years.

Children identified when they are older than 6 months can have speech and language delays. Children identified when they are younger than 6 months do not have these delays and are equal to their hearing peers in terms of speech and language.

Children younger than 12 months cannot be fitted with hearing aids.

Children as young as 1 month of age can be fit with and benefit from hearing aids.

Investigator, Year

State

Rate of Hearing Loss

Study Population

Connolly, 2005 [6]

Mississippi

1.00 / 811 (no risk)

1.00 / 75 (high risk)

17,602

Finitzo, 1998 [5]

Texas

3.14 / 1000

54,228

Vohr, 1998 [3]

Rhode Island

2.00 / 1000

53,121

Downs, 1995 [4]

Colorado

3.20 / 1000

14,404

Disorder

Rate per 100,000

Adrenal hyperplasia

2

Galactosemia

2

Phenylketonuria

3

Hypothyroid disease

28

Sickle cell disease

47

*Finitzio, 1999

Auditory Structure

OAEs

ABRs/AABRs

Outer ear

Yes

Yes

Middle ear

Yes

Yes

Inner ear

Yes

Yes

Auditory nerve

No

Yes

Auditory brainstem

No

Yes

Anne M Delaney, PhD Senior Audiologist, Coordinator of Newborn Hearing Program, Department of Otolaryngology-Head and Neck Surgery, University of Virginia Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Peter S Roland, MD Professor, Department of Neurological Surgery, Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, Director, Clinical Center for Auditory, Vestibular, and Facial Nerve Disorders, Chief of Pediatric Otology, University of Texas Southwestern Medical Center; Chief of Pediatric Otology, Children’s Medical Center of Dallas; President of Medical Staff, Parkland Memorial Hospital; Adjunct Professor of Communicative Disorders, School of Behavioral and Brain Sciences, Chief of Medical Service, Callier Center for Communicative Disorders, University of Texas School of Human Development

Peter S Roland, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American Neurotology Society, American Otological Society, North American Skull Base Society, Society of University Otolaryngologists-Head and Neck Surgeons, The Triological Society

Disclosure: Received honoraria from Alcon Labs for consulting; Received honoraria from Advanced Bionics for board membership; Received honoraria from Cochlear Corp for board membership; Received travel grants from Med El Corp for consulting.

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;Cliexa;Preacute Population Health Management;The Physicians Edge<br/>Received income in an amount equal to or greater than $250 from: The Physicians Edge, Cliexa<br/> Received stock from RxRevu; Received ownership interest from Cerescan for consulting; for: Rxblockchain;Bridge Health.

Russell A Faust, MD, PhD Consulting Staff, Department of Otolaryngology, Columbus Children’s Hospital

Disclosure: Nothing to disclose.

Roger A Ruth, PhD Director of Communication Disorders, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Virginia

Disclosure: Nothing to disclose.

Newborn Hearing Screening

Research & References of Newborn Hearing Screening|A&C Accounting And Tax Services
Source